Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROR2-specific monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ROR2-specific monoclonal antibody is a therapeutic agent designed to target and modulate the activity of Receptor Tyrosine Kinase-Like Orphan Receptor 2 (ROR2). In research related to pulmonary arterial hypertension (PAH), ROR2 has been identified as a key regulator of Wnt signaling balance in pulmonary pericytes. Overactivation and hyperphosphorylation of ROR2 in PAH pericytes drive phenotypic switching, leading to microvascular instability and vascular remodeling. This monoclonal antibody works by neutralizing aberrant ROR2 signaling, thereby restoring physiological Wnt signaling balance, stabilizing endothelial-pericyte interactions, and preserving microvascular homeostasis. It is currently being investigated in preclinical models for its potential to attenuate PAH progression.
- Other names
- anti-ROR2 monoclonal antibodyanti-ROR-2 monoclonal antibodyanti-ROR 2 monoclonal antibodyROR2 antibodyROR-2 antibodyROR 2 antibody
02
Targets
ROR2
Beyond the preview
Go deeper on ROR2-specific monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ROR2-specific monoclonal antibody.